Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q3 2023 Earnings Presentation

47 slides from Neurocrine Biosciences's earnings presentation, Oct 31, 2023

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q3 2023 Corporate Presentation October 31, 2023 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2023 Annual Net ~600,000 Sales Guidance to are affected by Tardive $1.82B to $1.84B Dyskinesia (TD) in the U.S. (~65% are undiagnosed) Multiple Compounds in R&D Focus Robust Mid- to Late-Stage Studies • Neurology Recent Milestones Include: Va

  4. Slide 4: Recent Highlights and Future Key Milestones and Activities

    Recent Highlights and Future Key Milestones and Activities Q3 2023 / Recent Highlights Future Key Milestones and Activities ▪ INGREZZA® (valbenazine) Q3 Net Product Sales of $486M ▪ Raised Full Year INGREZZA Net Sales Guidance for the Second Represents 29% YoY Growth vs. Q3 2022 Time in 2023 ▪ Recor

  5. Slide 5: Significant Milestones in 2023

    Significant Milestones in 2023 Valbenazine Crinecerfont NBI-921352 NBI-1065846 Chorea in Huntington’s Disease Congenital Adrenal Hyperplasia Focal Onset Seizures Anhedonia in MDD Positive Registrational PDUFA Approved Adult and Pediatric Phase 2 Data Phase 2 Data (August 20th) Top-Line Data Readouts

  6. Slide 6: Multiple Molecules and Mechanisms to Treat Intractable Diseases

    Multiple Molecules and Mechanisms to Treat Intractable Diseases NEUROLOGY NEUROENDOCRINOLOGY Chorea in SCN8A Adrenal Huntington’s Tardive Focal Onset Developmental Parkinson’s Endometriosis Uterine Fibroids Disease Insufficiency Disease (HD) Dyskinesia Seizures (FOS) and Epileptic FDA FDA APPROVED I

  7. Slide 7: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 Reviewing Full Data Set from Phase 2 Study to NBI-827104 Rare Pediatric Epilepsy: EE-CSWS Determine Next Steps NBI-921352 Focal

  8. Slide 8: Q3 2023 Financial Summary

    Q3 2023 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q3 2023 Q3 2022 Highlights / Comments Revenue $499 $388 Q3 2023 INGREZZA Sales of $486M Driven by Prescription - Product Sales, Net 492 379 Demand - Collaboration Revenue 7 9 Continued Support of Expanded / Advancing Clini

  9. Slide 9: Year-to-Date Financial Summary

    Year-to-Date Financial Summary $ Millions, Except Non-GAAP Earnings Per Share 2023 2022 Item Highlights / Comments YTD* YTD* Revenue $1,372 $1,077 YTD 2023 INGREZZA Sales of $1,336M Driven by Prescription - Product Sales, Net 1,353 1,036 Demand - Collaboration Revenue 19 40 Non-GAAP R&D Expense $373

  10. Slide 10: Raised 2023 INGREZZA Sales and Updated Operating Expense Guidance

    Raised 2023 INGREZZA Sales and Updated Operating Expense Guidance 2023 Previous 2023 Current Item ($ Millions) 2022 Actuals Comments Guidance Range Guidance Range INGREZZA Net Product Sales1 $1,428 $1,770 - $1,820 $1,820 - $1,840 Raising Range GAAP R&D Expense2 $464 $550 - $580 $560 - $570 Non-GAAP

  11. Slide 11: Corporate Sustainability

    Corporate Sustainability: Recently Upgraded at MSCI to “A” Rating Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality I

  12. Slide 12: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  13. Slide 13: Commercial Products Fueling Pipeline Investment

    Commercial Products Fueling Pipeline Investment In the U.S. In the U.S. and EU * ‡ TARDIVE DYSKINESIA NEW: CHOREA ASSOCIATED WITH HD ENDOMETRIOSIS ADRENAL INSUFFICIENCY In Europe ‡ † PARKINSON'S DISEASE UTERINE FIBROIDS Congenital Adrenal Hyperplasia *Mitsubishi Tanabe Pharma Corporation (MTPC) has

  14. Slide 14: INGREZZA

    INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES

  15. Slide 15: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) Q3 2023 Sales of $486M Represents $500 $486 29% Year-Over-Year Growth vs. Q3 2022 $450 $440 $410 $399 $400 $376 $350 $350 $301 $303 $300 $250 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 15

  16. Slide 16: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  17. Slide 17: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity Approximately 35% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. Increasing Antipsychotic Prescriptions (U.S.) ~35

  18. Slide 18: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Additional indication to treat NEW chorea associated with HD Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychot

  19. Slide 19: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  20. Slide 20: INGREZZA Approved by the FDA for Chorea Associated with Huntington's Disease

    INGREZZA® (Valbenazine) Approved by the FDA for the Treatment of Chorea Associated with Huntington’s Disease INGREZZA Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In randomized

  21. Slide 21: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy

    Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and

  22. Slide 22: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies

    NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies; Phase 2 FOS Study Fully Enrolled with Top-Line Data in Nov. 2023 Adult Focal Onset Seizures (FOS) Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the

  23. Slide 23: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  24. Slide 24: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  25. Slide 25: Classic CAH Due to 21-Hydroxylase Deficiency

    Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH) Cortisol Excess From High ACTH and • 21OHD CAH Results in: Supraphysiologic GC Dosing Androgen Excess ✓Impaired Synthesis of Cortisol and Cardiovascular Obesity Diabetes, Infertility Hirsutism, TARTs risk striae insu

  26. Slide 26: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  27. Slide 27: CAHtalyst Pediatric Study Design

    CAHtalystTM Pediatric Study Design Open- Double-Blind Placebo Controlled Treatment Open-Label Treatment Screening Label (28 weeks) (24 weeks) Extension* Crinecerfont Crinecerfont Placebo Day 1 Week 4 Week 28 Week 52* Primary Endpoint Participants randomized to Continued access to crinecerfont Measur

  28. Slide 28: CAHtalyst Adult Study Design

    CAHtalystTM Adult Study Design Open- Double-Blind Placebo Controlled Treatment Open-Label Treatment Screening Label (6 months) (one year) Extension* Crinecerfont Crinecerfont Placebo Day 1 Week 24 Month 18* Participants randomized to Continued access to crinecerfont placebo will receive crinecerfont

  29. Slide 29: CAHtalyst Adult and Pediatric Study Baseline Characteristics

    CAHtalystTM Adult and Pediatric Study Baseline Characteristics Adult Study Pediatric Study Study Characteristic (N = 182) (N = 103) Male / Female 51% Male 52% Male (Proportion of Total Subjects) 49% Female 48% Female Average Age 31 Years Old 12 Years Old (Age Ranges) (18 – 58 Years Old) (4 – 17 Year

  30. Slide 30: CAHtalyst Adult and Pediatric Study Common Endpoints

    CAHtalystTM Adult and Pediatric Study Common Endpoints Adult Study Pediatric Study Common Endpoints (p-values) (p-values) Serum Androstenedione – <0.0001 0.0002 Change from Baseline @ Week 4 Glucocorticoid Daily Dose – Percent Change from Baseline at Week 24 (Adult) / Week 28 (Pediatric) <0.0001 <0.

  31. Slide 31: Percent of Subjects Achieving Reduction to Physiologic GC Dose

    CAHtalystTM Adult and Pediatric Study Percent of Subjects Achieving Reduction to Physiologic GC Dose While Maintaining Androgen Control Percent of Subjects Achieving a Glucocorticoid Daily Dose ≤ 11 mg/m2/day While Maintaining Androgen Control CAHtalystTM Trial Participants Adult Study @ Week 24 Ped

  32. Slide 32: CAHtalyst Adult and Pediatric Study Safety and Tolerability

    CAHtalystTM Adult and Pediatric Study Safety and Tolerability • Crinecerfont Treatment was Overall Well-Tolerated with Few Serious Adverse Events (SAEs), None Were Assessed as Related to Crinecerfont • Most Common Adverse Events During the Double-Blind, Placebo-Controlled Period of the Adult Study w

  33. Slide 33: Crinecerfont Program Next Steps

    Crinecerfont Program Next Steps • The Open-Label Treatment Periods for the CAHtalystTM Pediatric and Adult Studies are Ongoing • Data from the CAHtalystTM Pediatric and Adult Studies, Including Data from the Ongoing Open- Label Treatment Periods, Will Support Regulatory Submissions to the FDA in 202

  34. Slide 34: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  35. Slide 35: Valbenazine: Registrational Programs in Adjunctive Treatment of Schizophrenia

    Valbenazine*: Registrational Programs in Adjunctive Treatment of Schizophrenia With Top-Line Data from 1st Study in 2024 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic m

  36. Slide 36: Potential First-in-Class Neuropsychiatry Programs

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in November 2023 (Study Fully Enrolled) Inadequate Response to Treatmen

  37. Slide 37: NBI-1065846: GPR139 Agonist

    NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben

  38. Slide 38: NBI-1065845: AMPA Potentiator

    NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants

  39. Slide 39: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu

  40. Slide 40: Developing Novel Muscarinic Receptor Agonist Portfolio

    Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential

  41. Slide 41: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2023 Annual Net ~600,000 Sales Guidance to are affected by Tardive $1.82B to $1.84B Dyskinesia (TD) in the U.S. (~65% are undiagnosed) Multiple Compounds in R&D Focus Robust Mid- to Late-Stage Studies • Neurology Recent Milestones Include: Va

  42. Slide 42: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  43. Slide 43: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) Revenues: Net product sales Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and dev

  44. Slide 44: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (x millions) Cash, cash equivalents and marketable securities Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Equity security investments Pro

  45. Slide 45: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) ‘Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share data) 2023, 2022 2023 2022 GAAP net income $ $3.1 $ 685 $ 102.0 $ 65.5 Adjustments: Stock-based compensation

  46. Slide 46: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) ‘Three Months Ended ‘Nine Months Ended September 30, I ‘(in millions) 2023 2022 2023 2022 GAAP cost of revenues $ Tia $ ai $ 32 BS Adjustments: Non-cash amortization related to acquired intang

  47. Slide 47: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q3 2023 Corporate Presentation October 31, 2023 Nasdaq: NBIX

Neurocrine Biosciences — Q3 2023 Earnings Presentation on 6ix